What’s New This Year?
Also new this year, a special poster session will facilitate communication among current and potential investigators about ongoing clinical trials of any phase. The purpose of this session is not to discuss preliminary data from ongoing trials with incomplete accrual, but rather to promote discussion among investigators, to encourage recruitment of new investigators or sites, and to stimulate discussion of successor or confirmatory trials.
Policies Related to Abstract Submission
Upon submission of an abstract to the ASCO Annual Meeting, the First Author must agree to the following Annual Meeting Abstract Policies on behalf of all parties involved with the abstract, including the Sponsor. The First Author is also responsible for communicating these Policies to all involved parties. If any of these policies are violated, the involved abstract may be removed from the Annual Meeting.
In addition to the policies above, the First Author is responsible for adhering to the ASCO Conflict of Interest Policy, obtaining disclosure information from all coauthors, and ensuring that all coauthors meet the definition of authorship as stated by the International Committee of Medical Journal Editors. Author disclosure for the First Author and all coauthors must be declared at the time of abstract submission. If the First Author is employed by a commercial interest as defined by ACCME, an alternate presenter who does not have a relevant employment relationship must be named if the abstract is selected for presentation in an Oral Abstract Session or Clinical Science Symposium.
Abstract Preparation and Submission
The First Author may submit only one abstract as First Author and must also agree to present if the abstract is selected for presentation at the Annual Meeting. Select the link below for a complete list of First Author responsibilities.
In order to submit an abstract as a nonmember, the First Author must obtain sponsorship from an ASCO Active or Active-Junior member. ASCO members may sponsor their own abstracts; ASCO Active or Active-Junior members may sponsor multiple abstracts in addition to their own.
The Abstract Submission website requires that certain information be entered in order for a submission to be considered complete.
Failure to comply with the ASCO abstract submission guidelines results in an infraction, which must be resolved before the abstract can be processed. To avoid unnecessary delays in the processing of your abstract or removal of the abstract, please review a list of common submission errors below.
Late-breaking Abstracts
The ASCO Late-breaking Abstracts Policy allows for the submission of Late-breaking Abstracts for randomized phase II and phase III trials for which no preliminary data are available at the time of the abstract submission deadline (January 12), but for which a preplanned analysis of the primary endpoint is scheduled after that date but before March 29 (deadline for the final, updated Late-breaking Abstract). The policy is not a mechanism to allow for updated data to be submitted later when preliminary data are available by the abstract submission deadline.
|
